EIQ FDA NSE letter delays heart failure solution timeline
EIQ said an FDA NSE letter for its heart failure solution delayed progress but did not derail it. Management is pursuing multiple regulatory pathways and maintaining high FDA engagement, supported by financial strength and an R&D pipeline.